Heidelberg Pharma Advances to Cohort 6 in Multiple Myeloma Study with HDP-101

Heidelberg Pharma AG, a clinical-stage biotech company, has announced its progression to Cohort 6 in the Phase I/IIa study of its ATAC candidate HDP-101 for multiple myeloma. This step comes after observing first objective responses and partial remissions in Cohort 5. The expanded Cohort 6 will undergo dose optimization through three parallel arms to enhance treatment efficacy and safety. This advancement showcases HDP-101's potential as a revolutionary treatment for multiple myeloma, a type of blood cancer affecting the bone marrow.

The study aims to evaluate the safety, tolerability, and efficacy of HDP-101 in patients with relapsed or refractory multiple myeloma. The inclusion of an amended protocol aims at optimizing the medication regimen. Positive outcomes from the initial cohorts have demonstrated HDP-101's safety and tolerability, with encouraging efficacy shown in Cohort 5. Further data from the ongoing study will be shared at scientific conferences in 2024.

Prof. Dr. Andreas Pahl, CEO of Heidelberg Pharma, expressed optimism about HDP-101's potential in changing the treatment landscape for multiple myeloma. The company plans to present detailed data on HDP-101 at the upcoming AACR Annual Meeting in April 2024.